By GLP-1 StudioGLP1Coach
← All tools

Free tool · GLP-1 comparison

Every GLP-1, compared simply.

Pick a medication, from Wegovy and Zepbound through to the newer ones still in development, and see what it is approved for, how it is taken, how it works, and what the trials found. You can also put two or more side by side when you are trying to understand the differences.

Available now

Coming

No longer made

Highlight up to 4 to compare them in a table.

This is education, not a recommendation

Which of these fits you, if any, depends on your health history, your insurance, and your prescriber's judgment. Trial percentages are averages from different trials with different lengths and populations, so treat them as a rough map, not a ranking. Bring this page to your appointment if it helps the conversation; do not use it in place of one.

Sources

12 references
  1. Wegovy (semaglutide) Prescribing Information. Novo Nordisk. Current label at DailyMed and the FDA label for Wegovy tablets. Indications including cardiovascular risk reduction and MASH, and the oral tablet approval.
  2. Zepbound (tirzepatide) Prescribing Information. Eli Lilly. FDA label. The weight-management and obstructive sleep apnea indications.
  3. Ozempic (semaglutide) injection Prescribing Information. Novo Nordisk. Current label. The type 2 diabetes, cardiovascular, and chronic kidney disease indications.
  4. Rybelsus and Ozempic (oral semaglutide) tablets Prescribing Information. Novo Nordisk. Current label at DailyMed. The one label now covering both names, and the source for the Ozempic tablet dosing and for the two products not being substitutable milligram for milligram.
  5. Foundayo (orforglipron) approval. Eli Lilly, 1 April 2026. Company announcement. The approval date, the weight-management indication, and the absence of food, water and timing restrictions.
  6. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183. The ~15% figure for semaglutide 2.4 mg.
  7. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038. The up-to-21% figure for tirzepatide 15 mg.
  8. Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). New England Journal of Medicine. 2015;373(1):11–22. doi:10.1056/NEJMoa1411892. The ~8% figure for liraglutide 3.0 mg.
  9. Wharton S, Blüher M, Deanfield J, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). New England Journal of Medicine. 2025;393(18):1796–1806. doi:10.1056/NEJMoa2511774. The ~12% (27 lb) average at the highest dose over 72 weeks.
  10. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE-1). New England Journal of Medicine. 2025;393(7):635–647. doi:10.1056/NEJMoa2502081. The 20.4% average on the treatment-policy estimand and 22.7% among those who stayed on full dosing, at 68 weeks.
  11. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972. The up-to-24% figure at 48 weeks.
  12. ASHP Drug Shortages Database: Exenatide. ashp.org. Documentation of the Byetta and Bydureon discontinuations.

Coaching

Would it help to talk this through with me?

A guide can lay out the options. Coaching helps you get ready for the conversation with your prescriber, the person who actually weighs them for you.

Work with me →